万赛维（缬更昔洛韦）作为胶质母细胞瘤患者标准治疗的附加药物。

Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients.

机构信息

Department of Medicine, Solna, Microbial Pathogenesis Unit, Karolinska Institutet, Stockholm, Sweden.

Division of Neurology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Clin Cancer Res. 2020 Aug 1;26(15):4031-4039. doi: 10.1158/1078-0432.CCR-20-0369. Epub 2020 May 18.

DOI:10.1158/1078-0432.CCR-20-0369

PMID:32423968

Abstract

PURPOSE

Several groups have reported a prevalence of human cytomegalovirus (CMV) in glioblastoma close to 100%. Previously, we reported that treatment with the antiviral drug valganciclovir as an add-on to standard therapy significantly prolonged survival in 50 patients with glioblastoma. Here, we present an updated retrospective analysis that includes an additional 52 patients.

EXPERIMENTAL DESIGN

From December 2006 to November 2019, 102 patients with newly diagnosed glioblastoma received valganciclovir as an add-on to standard therapy. No additional toxicity was observed. Contemporary controls were 231 patients with glioblastoma who received similar baseline therapy.

RESULTS

Patients with newly diagnosed glioblastoma receiving valganciclovir had longer median overall survival (OS 24.1 vs. 13.3 months, < 0.0001) and a 2-year survival rate (49.8% vs. 17.3%) than controls. Median time-to-tumor progression was also longer than in controls; 9.9 (0.7-67.5 months) versus 7.3 (1.2-49 months), = 0.0003. Valganciclovir improved survival in patients with radical or partial resection and an unmethylated or methylated promoter gene.

CONCLUSIONS

Valganciclovir prolonged median OS of patients with newly diagnosed glioblastoma (with methylated or unmethylated promoter gene) and was safe to use.

摘要

目的

有几个研究小组报告称，胶质母细胞瘤中人类巨细胞病毒（CMV）的患病率接近 100%。此前，我们报告称，作为标准治疗的附加治疗，使用抗病毒药物缬更昔洛韦显著延长了 50 名胶质母细胞瘤患者的生存时间。在此，我们呈现了一项更新的回顾性分析，其中包括另外 52 名患者。

实验设计

从 2006 年 12 月至 2019 年 11 月，102 名新诊断为胶质母细胞瘤的患者接受了缬更昔洛韦作为标准治疗的附加治疗。未观察到额外的毒性。同期对照组为 231 名接受类似基线治疗的胶质母细胞瘤患者。

结果

接受缬更昔洛韦治疗的新诊断为胶质母细胞瘤的患者中位总生存期（OS）更长（24.1 个月 vs. 13.3 个月，<0.0001），2 年生存率（49.8% vs. 17.3%）更高。与对照组相比，中位肿瘤进展时间也更长；9.9（0.7-67.5 个月）vs. 7.3（1.2-49 个月），=0.0003。缬更昔洛韦改善了根治性或部分切除术患者以及甲基化或非甲基化启动子基因患者的生存。